WEHI (Walter and Eliza Hall Institute of Medical Research)’s Post

Breast cancer metastases can occur years after quiescence and cause cancer relapse as disseminated tumor cells (DCTs) resist treatment and survive – dormant – in distant organs and get activated once again. How these cells can be detected, specified and treated remains one of the big challenges in breast cancer. Click the picture and read how in vitro models can provide insights into mechanisms, triggers, and cell responses and how these could be transferred and used in a clinical setting. #personalizedmedicine #breastcancer #oncology #cancerresearch

Some interesting fundamental research here from NCI/NIH: to improve the effectiveness of T-cell therapy against solid tumors, researchers at NCI’s Center for Cancer Research engineered T cells (CAR T cells and another form of cellular immunotherapy called TCR T cells) to carry cytokines, which are proteins that can boost T-cell function. #cartcells #immunotherapy #celltherapy #cancerresearch #cancer #cancertreatment #medicine #research #cityofhope I'm surprised that engineering the CAR T cells with cytokines didn't trigger more CRS. https://lnkd.in/gzuAkpAS

Combining tissue and liquid biopsy improves cancer care by detecting mutations more effectively, especially for cases like breast cancer. The study with 3,209 ethnically diverse patients affirms the clinical utility of using both liquid biopsy and tissue samples in identifying actionable variants among patients with advanced cancer. Click here to read more: https://bit.ly/47RroWS #liquidbiopsy #nextgenerationsequencing #venturecapital #privateequity #deerbornedifference

According to the 2023 ESMO Immuno-Oncology Awardee, Steven A. Rosenberg, the keys to progress in cell-based immunotherapies are identifying the optimal characteristics of antitumour effector lymphocytes, cancer antigen identification and strategies for overcoming resistance mechanisms to enhance immune-cell function. Discover the full interview in the #ESMODailyReporter and dive deeper into the challenges and opportunities of this field. 👉https://ow.ly/9Kwi50QfURR

According to early clinical data, a new experimental blood test can detect stage 1 and 2 pancreatic cancer with 97% accuracy. Although pancreatic cancer accounts for just 3% of new cancer diagnoses, it's one of the most fatal due to the difficulty of detecting it at an early stage. A quicker and earlier diagnosis means it's much more likely the cancer can be surgically removed before it spreads to other parts of the body, significantly increasing the likelihood of a full recovery. The clinical trial included patients from the US and Asia and will now be studied on a larger scale. #liquidbiopsy #IVD #cancerdiagnostics

🔥 Hot off the press! We are excited to announce the release of our latest article shedding light on the groundbreaking research conducted by our talented PhD candidate, Astrid Van den Eynde. Delving into the intricacies of CAR NK cells targeting tumor cells and cancer-associated fibroblasts in both pancreatic and colorectal cancer, this work marks a significant stride in oncological advancement. 🙏🏻 Proudly supported by Kom op tegen Kanker (vzw). ➡️ Dive into the full article through the link below. Jonas Van Audenaerde Evelien Smits #CancerResearch #CARNK #Celltherapy

Why do some breast cancer cells resist treatment? For patients with early-stage breast cancer, there is a 7 to 11 per cent chance of relapse within five years after receiving initial treatment, and this rate can be higher for patients with more advanced stage of the cancer. While chemotherapy aims to eliminate all #cancer #cells, some of them may evade treatment and survive, resulting in recurrence of the cancer. Led by #Research Asst Prof Leong Sai Mun from the NUS Centre for Cancer Research and the Department of Pathology at #NUSMedicine, a study that spanned over 10 years discovered that certain breast tumour cells sacrifice their own growth to aid other cells in resisting chemotherapy. This discovery reveals that disrupting such cooperation could be key to developing more effective treatments for breast cancer. Read more here: https://lnkd.in/gW9DwD_W #NewsAndUpdates

“Head and neck cancer is becoming a major problem so anything we can do to cure or improve the lives of our patients is a major step forward. I think this research gets us closer to that goal," says CU Cancer Center member Sana Karam, MD, PhD, about her study of how drugs like Botox may slow the progression of malignancies. “We want to get to the bottom of the mechanisms behind this so we can develop better therapeutics for patients who cannot tolerate chemotherapy or radiation,” Karam said. “We are looking at nerves firing and seeing how we can block them at the terminal end and investigate how that affects cancer growth.” Learn more about this study here: https://lnkd.in/gKRXYziw #HeadAndNeckCancerAwarenessMonth #HeadAndNeckCancerAwareness #HeadAndNeckCancer #Oncology #Cancer #Research

I am deeply grateful to Prof. Su Bin Lim for the opportunity to contribute to the publication of our article, “NAMPT-Driven M2 Polarization of Tumor-Associated Macrophages Leads to an Immunosuppressive Microenvironment in Colorectal Cancer.” Being part of this impactful research is truly an honor. The work represents a significant step forward in understanding the complexities of the tumor immune microenvironment and its implications for colorectal cancer therapy. For those interested in the details of our findings, you can access the paper here: https://lnkd.in/gzp-VfCK #CancerResearch #ColorectalCancer #ScientificPublication

Hopefully, a step forward. Promising, but very preliminary results using CAR-T cancer therapy technology. Keep your eyes on this space. CAR-T therapy involves harvesting a person’s own immune cells and modifying them in a lab to seek out specific tumor proteins. The cells are then reintroduced into the body where they replicate, creating a surge of cancer-fighting immune cells. https://lnkd.in/gFUvrsWe